Specifically, CCL19 (0.001 versus 0.02, p = 0.01, Figure 4(a)) and CCL21 (0.00 versus 0.04, p = 0.02, Figure 4(b)) mRNA levels were significantly reduced in COPD BM-MSCs compared to controls (Table 5). This evidence concerns the gene CCL19 and chronic obstructive pulmonary disease.